Neurology News

Narrow your search for Mass General Neurology news by using the search box and/or filters.
    160 results
    • news

    Daylight saving time: Easing the transition

    Daylight saving time: Easing the transition. Daylight saving time: Easing the transition. This year, daylight saving time begins at 2 am on March 8. Here, Elizabeth Klerman, MD, PhD, of the MGH Department of Neurology, discusses possible side effects

    • news

    2020 South Florida Neuroscience Symposium

    This symposium is a 2 day educational and networking forum designed for physicians,nurses, advanced practitioners, pharmacists, allied health professionals, researchers,and students with a focus on the emerging science of genetic therapies and theevaluation, management, and treatment of Alzheimer's Disease, ALS, brain tumors and metastases, and stroke.

    • press release

    Study reveals insights on hidden sexual-arousal disorder

    Study reveals insights on hidden sexual-arousal disorder. Study reveals insights on hidden sexual-arousal disorder. Key Takeaways • Persistent genital arousal disorder is characterized by spontaneous and unwanted sexual arousal unrelated to desire

    • news

    Healey Science Advisory Council Meets in Orlando, Florida

    Highlights from the meeting included a robust discussion moderated by Dr. Robert Brown with guest speakers Drs. Jean-Pierre Julien, from Laval Universities Department of Psychiatry and Neuroscience, Saud Sadiq, Director and Chief Research Scientist from Tisch MS Research Center of New York and Laura Paulsen, from EnClear Therapies, who spoke on the role of CSF toxicity in ALS pathophysiology.

    • press release

    Inaugural Mass General Hospital HEALEY Center International Prize for Innovation in ALS Awarded at 2019 MND Meeting in Perth, Australia

    The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the inaugural annual Healey Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS) to the team that brought to trial the first antisense oligonucleotide (ASO) therapy for ALS. Team members include researchers from academia and industry.

    Showing 1 - 10 of 160 results